Parthenolide attenuated the endometriosis-like lesions by activating autophagy and suppressing NLRP3 inflammasome activity

Document Type : Original Article

Authors

1 Department of Gynecology and Obstetrics, The Fourth Affiliated Hospital of Soochow University, Suzhou 215000, China

2 Department of Orthopedics, The Fourth Affiliated Hospital of Soochow University, Suzhou 215000, China

3 Nanjing University of Chinese Medicine, Nanjing 210003, China

10.22038/ijbms.2025.90575.19521

Abstract

Objective(s): Parthenolide (PTL) has significant anti-inflammatory and immunomodulatory effects, but its regulatory mechanisms in endometriosis (EMs) remain unclear. This study aimed to systematically evaluate the effects of PTL on cellular models and a murine EMs model, with a focus on its regulatory roles in autophagy and the NLRP3 inflammasome pathway.
Materials and Methods: Human monocytic leukemia THP-1 cells, murine immortalized bone marrow-derived macrophages, and 30 female C57BL/6 mice were used. Autophagy-related proteins (Beclin1, LC3, p62) and inflammasome components (NLRP3, ASC, caspase-1) were detected by Western blotting, and the activation of the AMPK/ULK1 signaling pathway was assessed after treating with PTL at a concentration of 10 mg/ml for 1 hr. A murine EMs model was established by peritoneal implantation, followed by intraperitoneal injections of PTL (10 mg/ml). Immunohistochemical staining was performed to detect the expression of NLRP3, caspase-1, IL-1β, and GSDMD in ectopic lesions.
Results: In vitro, PTL (10 mg/ml) significantly inhibited the activation of NLRP3, caspase-1-p20, IL-1β, and GSDMD, while increasing the phosphorylation levels of Beclin1 and AMPK/ULK1, and decreasing the expression of p62 and LC3, indicating enhanced autophagic flux. In vivo, PTL treatment markedly reduced the number, surface area, and weight of ectopic lesions in mice, and significantly suppressed the expression of inflammatory proteins in the lesions.
Conclusion: PTL exerts its therapeutic effect on EMs by simultaneously activating autophagy through the AMPK/ULK1 signaling pathway and inhibiting the NLRP3 inflammasome and its downstream effectors.

Keywords

Main Subjects

References

1. Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol 2019; 15:666-682.
2.    Gu Z, Li X, Shi J, Wu Y, Zhang J, Zhang C, et al. The development of predictive nomogram of recurrence for patients with endometrioma after cystectomy who were younger than 45 years old and received postoperative therapy. Front Med (Lausanne) 2022; 9:872481.
3.    Surrey ES. GnRH agonists in the treatment of symptomatic endometriosis: A review. F S Rep 2023; 4:40-45.
4.    Dolmans MM, Donnez J. Emerging drug targets for endometriosis. Biomolecules 2022; 12:1654-1667.
5.    Li W, Lin A, Qi L, Lv X, Yan S, Xue J, et al. Immunotherapy: A promising novel endometriosis therapy. Front Immunol 2023; 14:1128301.
6.    Zhan L, Li J, Wei B. Autophagy in endometriosis: Friend or foe? Biochem Biophys Res Commun 2018; 495:60-63.
7.    Bullon P, Navarro JM. Inflammasome as a Key Pathogenic Mechanism in Endometriosis. Curr Drug Targets 2017; 18:997-1002.
8.    Laganà AS, Garzon S, Götte M, Viganò P, Franchi M, Ghezzi F, et al. The pathogenesis of endometriosis: Molecular and cell biology insights. Int J Mol Sci 2019; 20:5615-5656.
9.    Kobayashi H, Imanaka S, Yoshimoto C, Matsubara S, Shigetomi H. Molecular mechanism of autophagy and apoptosis in endometriosis: Current understanding and future research directions. Reprod Med Biol 2024; 23:e12577.
10.    Biasizzo M, Kopitar-Jerala N. Interplay between NLRP3 inflammasome and autophagy. Front Immunol 2020; 11:591803.
11.    Siracusa R, D’Amico R, Impellizzeri D, Cordaro M, Peritore AF, Gugliandolo E, et al. Autophagy and mitophagy promotion in a rat model of endometriosis. Int J Mol Sci 2021; 22:5074-5085.
12.    Choi J, Jo M, Lee E, Kim SE, Lee DY, Choi D. Inhibition of the NLRP3 inflammasome by progesterone is attenuated by abnormal autophagy induction in endometriotic cyst stromal cells: Implications for endometriosis. Mol Hum Reprod 2022; 28: gaac007.
13.    Liu L, Feng L, Gao J, Hu J, Li A, Zhu Y, et al. Parthenolide targets NLRP3 to treat inflammasome-related diseases. Int Immunopharmacol 2023; 119:110229.
14.    Li K, Chen Y, Lin Y, Zhang G, Su J, Wu X, et al. PD-1/PD-L1 blockade is a potent adjuvant in treatment of Staphylococcus aureus osteomyelitis in mice. Mol Ther 2023; 31:174-192.
15.    Castillo EF, Dekonenko A, Arko-Mensah J, Mandell MA, Dupont N, Jiang S, et al. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc Natl Acad Sci U S A 2012; 109:E3168-3176.
16.    Takai E, Taniguchi F, Nakamura K, Uegaki T, Iwabe T, Harada T. Parthenolide reduces cell proliferation and prostaglandin E2 [corrected] in human endometriotic stromal cells and inhibits development of endometriosis in the murine model. Fertil Steril 2013; 100:1170-1178.
17.    Oală IE, Mitranovici MI, Chiorean DM, Irimia T, Crișan AI, Melinte IM, et al. Endometriosis and the role of pro-inflammatory and anti-inflammatory cytokines in pathophysiology: a narrative review of the literature. Diagnostics (Basel) 2024; 14:312-328.
18.    Sun Q, Fan J, Billiar TR, Scott MJ. Inflammasome and autophagy regulation - a two-way street. Mol Med 2017; 23:188-195.
19.    Mathema VB, Koh YS, Thakuri BC, Sillanpää M. Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities. Inflammation 2012; 35:560-565.
20.    Zhu S, Sun P, Bennett S, Charlesworth O, Tan R, Peng X, et al. The therapeutic effect and mechanism of parthenolide in skeletal disease, cancers, and cytokine storm. Front Pharmacol 2023; 14:1111218.
21.    Curry EA 3rd, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 2004; 22:299-305.
22.    Murakami M, Osuka S, Muraoka A, Hayashi S, Bayasula, Kasahara Y, et al. Effectiveness of NLRP3 inhibitor as a nonhormonal treatment for ovarian endometriosis. Reprod Biol Endocrinol 2022; 20:58-69.
23.    Xue Y, Enosi Tuipulotu D, Tan WH, Kay C, Man SM. Emerging activators and regulators ofinflammasomes and pyroptosis. Trends Immunol 2019; 40:1035-1052.
24.    Kato T, Yasuda K, Matsushita K, Ishii KJ, Hirota S, Yoshimoto T, et al. Interleukin-1/-33 signaling pathways as therapeutic targets for endometriosis. Front Immunol 2019; 10:1-12.
25.    Ogasawara Y, Cheng J, Tatematsu T, Uchida M, Murase O, Yoshikawa S, et al. Long-term autophagy is sustained by activation of CCTβ3 on lipid droplets. Nat Commun 2020; 11:4480-4491.
26.    Dong S, Wang Q, Kao YR, Diaz A, Tasset I, Kaushik S, et al. Chaperone-mediated autophagy sustains haematopoietic stemcell function. Nature 2021; 591:117-123.
27.    He R, Liu X, Zhang J, Wang Z, Wang W, Fu L, et al. NLRC5 inhibits inflammation of secretory phase ectopic endometrial stromal cells by up-regulating autophagy in ovarian endometriosis. Front Pharmacol 2020; 11:1281-1293.
28.    Yu Q, Shi H, Ding Z, Wang Z, Yao H, Lin R. The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation in Helicobacter pylori-associated gastritis by regulating ROS and autophagy. Cell Commun Signal 2023; 21:1-16.
29.    Ding Y, Fu X, Wang Q, Liu H, Wang H, Wu D. The complex interplay between autophagy and NLRP3 inflammasome in renal diseases. Int J Mol Sci 2021; 22:12766-12778.
Iranian Journal of Basic Medical Sciences
Volume 29, Issue 1
January 2026
Pages 90-100

Files

Share

How to cite

Statistics